ArticleActa oncologica (Stockholm, Sweden)2025
Five-year follow-up of patients with low-risk papillary thyroid cancer treated without postoperative radioiodine: prospective study by the Finnish Thyroid Cancer Group.
Article in Acta oncologica (Stockholm, Sweden), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThe purpose of this study was to evaluate the safety of omitting radioiodine (RAI) ablation in low-risk papillary thyroid cancer. PATIENTS AND
methodsAll five university hospitals in Finland consecutively and prospectively enrolled patients in the study with the following inclusion criteria: age 18 or over, papillary unifocal, intrathyroidal cancer 11-20 mm operated with a thyroidectomy, and no lymph node metastases. All patients were initially offered a follow-up without RAI. The patients who did not receive postoperative RAI were included in the RAILESS group. Those who preferred to have RAI and those who received RAI due to elevated thyroglobulin (TG) or thyroglobulin antibodies (TGAb) formed the RAIRINN group. Thyroglobulin and TGAb levels were monitored 4-8 weeks postoperatively in the RAILESS group. All patients were subsequently monitored every 3 months for the first year and then annually for 5 years, with a neck ultrasound. Radioiodine was administered if TG surpassed 2 ug/L or TGAb exceeded 40 kU/L in two consecutive measurements. An event was defined as a structural recurrence or a biochemical abnormality resulting in RAI treatment. The primary endpoint was the amount of patients who remained event-free during a 5-year follow-up.
resultsFifty-three of 60 patients enrolled were assigned to the RAILESS and 5 to the RAIRINN group. In the RAILESS group, 96% (51/53) remained event-free throughout 5 years, while 4% (2/53) required RAI due to increased TG or TGAb levels. In the RAIRINN group, one patient (1/7 or 14%) developed a metastatic disease.
interpretationOur findings provide additional evidence for safely omitting postoperative RAI in low-risk papillary thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.